Xtant Medical (XTNT) Expected to Announce Quarterly Earnings on Thursday

Xtant Medical (NYSEAMERICAN:XTNT) is projected to release its earnings data after the market closes on Thursday, March 6th. Analysts expect Xtant Medical to post earnings of ($0.02) per share and revenue of $31.80 million for the quarter.

Xtant Medical Stock Performance

XTNT stock opened at $0.45 on Tuesday. The company has a current ratio of 2.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.42. Xtant Medical has a 1 year low of $0.33 and a 1 year high of $1.24. The firm has a market capitalization of $62.55 million, a PE ratio of -3.46 and a beta of 0.35.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.